The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Clin Liver Dis. 2018;11:81–81.
Blond E, Disse E, Cuerq C, Drai J, Valette P-J, Laville M, Thivolet C, Simon C, Caussy C. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral? Diabetologia. 2017;60:1218–22.
Eslam M, Sarin SK, Wong VW-S, Fan J-G, Kawaguchi T, Ahn SH, Zheng M-H, Shiha G, Yilmaz Y, Gani R, Alam S, Dan YY, Kao J-H, Hamid S, Cua IH, Chan W-K, Payawal D, Tan S-S, Tanwandee T, Adams LA, Kumar M, Omata M, George J. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14:889–919.
Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, Zelber-Sagi S, Wai-Sun Wong V, Dufour J-F, Schattenberg JM, Kawaguchi T, Arrese M, Valenti L, Shiha G, Tiribelli C, Yki-Järvinen H, Fan J-G, Grønbæk H, Yilmaz Y, Cortez-Pinto H, Oliveira CP, Bedossa P, Adams LA, Zheng M-H, Fouad Y, Chan W-K, Mendez-Sanchez N, Ahn SH, Castera L, Bugianesi E, Ratziu V, George J. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202–9.
Brunt EM, Wong VWS, Nobili V, Day CP, Sookoian S, Maher JJ, Bugianesi E, Sirlin CB, Neuschwander-Tetri B, Rinella ME. Nonalcoholic fatty liver disease. Nat Rev Dis Primers. 2015;1.
Kendall TJ, Jimenez-Ramos M, Turner F, Ramachandran P, Minnier J, McColgan MD, Alam M, Ellis H, Dunbar DR, Kohnen G, Konanahalli P, Oien KA, Bandiera L, Menolascina F, Juncker-Jensen A, Alexander D, Mayor C, Guha IN, Fallowfield JA. An integrated gene-to-outcome multimodal database for metabolic dysfunction-associated steatotic liver disease. Nat Med. 2023.
Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:908–22.
Bedossa P, Poitou C, Veyrie N, Bouillot J-L, Basdevant A, Paradis V, Tordjman J, Clement K. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology. 2012;56:1751–9.
Younossi ZM. Non-alcoholic fatty liver disease—a global public health perspective. J Hepatol. 2019;70:531–44.
Lonardo A, Byrne CD, Caldwell SH, Cortez-Pinto H, Targher G. Global epidemiology of nonalcoholic fatty liver disease: meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:1388–9.
Wang Y-D, Wu L-L, Qi X-Y, Wang Y-Y, Liao Z-Z, Liu J-H, Xiao X-H. New insight of obesity-associated NAFLD: dysregulated “crosstalk” between multi-organ and the liver? Genes Dis. 2023;10:799–812.
Huang W, Wang G, Xia Y, Xiong Z, Ai L. Bile salt hydrolase-overexpressing Lactobacillus strains can improve hepatic lipid accumulation in vitro in an NAFLD cell model. Food Nutr Res. 2020;64.
Chandrasekaran VRM, Hsu D-Z, Chien S-P, Liu M-Y. Co-exposure of arsenic and iron causes hepatic injury: a tale of two hits. Epidemiology. 2009;20:S125–S125.
Cheng C, Zhuo S, Zhang B, Zhao X, Liu Y, Liao C, Quan J, Li Z, Bode AM, Cao Y, Luo X. Treatment implications of natural compounds targeting lipid metabolism in nonalcoholic fatty liver disease, obesity and cancer. Int J Biol Sci. 2019;15:1654–63.
Parekh S, Anania FA. Abnormal lipid and glucose metabolism in obesity: Implications for nonalcoholic fatty liver disease. Gastroenterology. 2007;132:2191–207.
Gaggini M, Carli F, Rosso C, Buzzigoli E, Marietti M, Della Latta V, Ciociaro D, Abate ML, Gambino R, Cassader M, Bugianesi E, Gastaldelli A. Altered amino acid concentrations in NAFLD: impact of obesity and insulin resistance. Hepatology. 2018;67:145–58.
Masoodi M, Gastaldelli A, Hyotylainen T, Arretxe E, Alonso C, Gaggini M, Brosnan J, Anstee QM, Millet O, Ortiz P, Mato JM, Dufour J-F, Oresic M. Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. Nat Rev Gastroenterol Hepatol. 2021;18:835–56.
Lake AD, Novak P, Shipkova P, Aranibar N, Robertson DG, Reily MD, Lehman-McKeeman LD, Vaillancourt RR, Cherrington NJ. Branched chain amino acid metabolism profiles in progressive human nonalcoholic fatty liver disease. Amino Acids. 2015;47:603–15.
Gaggini M, Carli F, Rosso C, Younes R, D’Aurizio R, Bugianesi E, Gastaldelli A. Altered metabolic profile and adipocyte insulin resistance mark severe liver fibrosis in patients with chronic liver disease. Int J Mol Sci. 2019;20.
Grzych G, Vonghia L, Bout M-A, Weyler J, Verrijken A, Dirinck E, Curt MJC, Van Gaal L, Paumelle R, Francque S, Tailleux A, Haas JT, Staels B. Plasma BCAA changes in patients with NAFLD are sex dependent. J Clin Endocrinol Metab. 2020;105:2311–21.
Trico D, Biancalana E, Solini A. Protein and amino acids in nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care. 2021;24:96–101.
Psychogios N, Hau DD, Peng J, Guo AC, Mandal R, Bouatra S, Sinelnikov I, Krishnamurthy R, Eisner R, Gautam B, Young N, Xia J, Knox C, Dong E, Huang P, Hollander Z, Pedersen TL, Smith SR, Bamforth F, Greiner R, McManus B, Newman JW, Goodfriend T, Wishart DS. The human serum metabolome. Plos One. 2011;6.
Petrus P, Lecoutre S, Dollet L, Wiel C, Sulen A, Gao H, Tavira B, Laurencikiene J, Rooyackers O, Checa A, Douagi I, Wheelock CE, Arner P, McCarthy M, Bergo MO, Edgar L, Choudhury RP, Aouadi M, Krook A, Ryden M. Glutamine links obesity to inflammation in human white adipose tissue. Cell Metab. 2020;31:375.
Crunkhorn S. Type 2 diabetes: targeting glutamine metabolism. Nat Rev Drug Discovery. 2018;17:316–316.
Simon J, Martinez-Chantar ML, Delgado TC. Glutamine, fatty liver disease and aging. Aging. 2021;13:3165–6.
Cluntun AA, Lukey MJ, Cerione RA, Locasale JW. Glutamine metabolism in cancer: understanding the heterogeneity. Trends Cancer. 2017;3:169–80.
Chashmniam S, Ghafourpour M, Farimani AR, Gholami A, Ghoochani BFNM. Metabolomic biomarkers in the diagnosis of non-alcoholic fatty liver disease. Hepat Mon. 2019;19.
Kaikkonen JE, Wuertz P, Suomela E, Lehtovirta M, Kangas AJ, Jula A, Mikkilae V, Viikari JSA, Juonala M, Roennemaa T, Hutri-Kaehoenen N, Kaehoenen M, Lehtimaeki T, Soininen P, Ala-Korpela M, Raitakari OT. Metabolic profiling of fatty liver in young and middle-aged adults: cross-sectional and prospective analyses of the young finns study. Hepatology. 2017;65:491–500.
Santos DOR, Cardoso DSG, Lima DCL, de Sousa Cavalcante ML, Silva MS, Cavalcante Martins AK, Severo JS, de Melo Sousa FB, Pacheco G, Alves Pereira EH, NobreSoares LM, Medeiros Rolim JV, Lima-Junior RC, dos Santos AA, Tolentino M. L-glutamine and physical exercise prevent intestinal inflammation and oxidative stress without improving gastric dysmotility in rats with ulcerative colitis. Inflammation. 2021;44:617–32.
Chakravarthy MV, Waddell T, Banerjee R, Guess N. Nutrition and nonalcoholic fatty liver disease current perspectives. Gastroenterol Clin N Am. 2020;49:63.
Stojanovic O, Altirriba J, Rigo D, Spiljar M, Evrard E, Roska B, Fabbiano S, Zamboni N, Maechler P, Rohner-Jeanrenaud F, Trajkovski M. Dietary excess regulates absorption and surface of gut epithelium through intestinal PPARalpha. Nat Commun. 2021;12:7031–7031.
Stojanović O, Altirriba J, Rigo D, Spiljar M, Evrard E, Roska B, Fabbiano S, Zamboni N, Maechler P, Rohner-Jeanrenaud F, Trajkovski M. Dietary excess regulates absorption and surface of gut epithelium through intestinal PPARα. Nat Commun. 2021;12:7031.
Chaudhry KK, Shukla PK, Mir H, Manda B, Gangwar R, Yadav N, McMullen M, Nagy LE, Rao R. Glutamine supplementation attenuates ethanol-induced disruption of apical junctional complexes in colonic epithelium and ameliorates gut barrier dysfunction and fatty liver in mice. J Nutr Biochem. 2016;27:16–26.
Abboud KY, Reis SK, Martelli ME, Zordao OP, Tannihao F, de Souza AZZ, Assalin HB, Guadagnini D, Rocha GZ, Saad MJA, Prada PO. Oral glutamine supplementation reduces obesity, pro-inflammatory markers, and improves insulin sensitivity in DIO wistar rats and reduces waist circumference in overweight and obese humans. Nutrients. 2019;11.
Bock PM, Krause M, Schroeder HT, Hahn GF, Takahashi HK, Schoeler CM, Nicoletti G, ZavarizeNeto LD, Lavina Rodrigues MI, Bruxel MA, Homem de Bittencourt PI. Oral supplementations with L-glutamine or L-alanyl-L-glutamine do not change metabolic alterations induced by long-term high-fat diet in the B6.129F2/J mouse model of insulin resistance. Mol Cell Biochem. 2016;411:351–62.
Olaniyi KS, Olatunji LA. Inhibition of pyruvate dehydrogenase kinase-4 by L-glutamine protects pregnant rats against fructose-induced obesity and hepatic lipid accumulation. Biomed Pharmacother. 2019;110:59–67.
Qiu J, Yue F, Zhu P, Chen J, Xu F, Zhang L, Kim KH, Snyder MM, Luo N, Xu H-W, Huang F, Tao WA, Kuang S. FAM210A is essential for cold-induced mitochondrial remodeling in brown adipocytes. Nat Commun. 2023;14:6344.
Spiegelman BM, Flier JS. Obesity and the regulation of energy balance. Cell. 2001;104:531–43.
Torres-Villalobos G, Hamdan-Perez N, Tovar AR, Ordaz-Nava G, Martinez-Benitez B, Torre-Villalvazo I, Moran-Ramos S, Diaz-Villasenor A, Noriega LG, Hiriart M, Medina-Santillan R, del Carmen C-H, Mendez-Sanchez N, Uribe M, Torres N. Combined high-fat diet and sustained high sucrose consumption promotes NAFLD in a murine model. Ann Hepatol. 2015;14:540–6.
Wu T, Little TJ, Bound MJ, Borg M, Zhang X, Deacon CF, Horowitz M, Jones KL, Rayner CK. A protein preload enhances the glucose-lowering efficacy of vildagliptin in type 2 diabetes. Diabetes Care. 2016;39:511–7.
Chang J, Wu T, Greenfield JR, Samocha-Bonet D, Horowitz M, Rayner CK. Effects of intraduodenal glutamine on incretin hormone and insulin release, the glycemic response to an intraduodenal glucose infusion, and antropyloroduodenal motility in health and type 2 diabetes. Diabetes Care. 2013;36:2262–5.
da Rosa CVD, Azevedo SCSF, Bazotte RB, Peralta RM, Buttow NC, Pedrosa MMD, de Godoi VAF, Natali MRM. Supplementation with L-glutamine and L-alanyl-L-glutamine changes biochemical parameters and jejunum morphophysiology in type 1 diabetic wistar rats. PLoS ONE. 2015;10: e0143005.
Alba-Loureiro TC, Ribeiro RF, Tenorio Zorn TM, Lagranha CJ. Effects of glutamine supplementation on kidney of diabetic rat. Amino Acids. 2010;38:1021–30.
da Rosa CVD, Azevedo SCSF, Bazotte RB, Peralta RM, Buttow NC, Pedrosa MMD, de Godoi VAF, Natali MRM. Supplementation with L-glutamine and L-alanyl-L-glutamine changes biochemical parameters and jejunum morphophysiology in type 1 diabetic wistar rats. Plos One. 2015;10.
Wang J-l, Ding H-r, Pan C-y, Shi X-l, Ren H-z. Mesenchymal stem cells ameliorate lipid metabolism through reducing mitochondrial damage of hepatocytes in the treatment of post-hepatectomy liver failure. Cell Death Dis. 2021;12.
Masarone M, Rosato V, Dallio M, Gravina AG, Aglitti A, Loguercio C, Federico A, Persico M. Role of oxidative stress in pathophysiology of nonalcoholic fatty liver disease. Oxid Med Cell Longev. 2018;2018.
Spahis S, Delvin E, Borys J-M, Levy E. Oxidative stress as a critical factor in nonalcoholic fatty liver disease pathogenesis. Antioxid Redox Signal. 2017;26:519.
Barbosa CP, Bracht L, Ames FQ, de Souza Silva-Comar FM, Tronco RP, Bersani-Amado CA. Effects of ezetimibe, simvastatin, and their combination on inflammatory parameters in a rat model of adjuvant-induced arthritis. Inflammation. 2017;40:717–24.
Tsai P-H, Liu J-J, Chiu W-C, Pai M-H, Yeh S-L. Effects of dietary glutamine on adhesion molecule expression and oxidative stress in mice with streptozotocin-induced type 1 diabetes. Clin Nutr. 2011;30:124–9.
Longo M, Paolini E, Meroni M, Dongiovanni P. Remodeling of mitochondrial plasticity: the key switch from NAFLD/NASH to HCC. Int J Mol Sci. 2021;22.
Ajaz S, McPhail MJ, Gnudi L, Trovato FM, Mujib S, Napoli S, Carey I, Agarwal K. Mitochondrial dysfunction as a mechanistic biomarker in patients with non-alcoholic fatty liver disease (NAFLD). Mitochondrion. 2021;57:119–30.
Zhao Q-Y, Ge L-H, Zhang K, Chen H-F, Zhan X-X, Yang Y, Dang Q-L, Zheng Y, Zhou H-B, Lyu J-X, Fang H-Z. Assessment of mitochondrial function in metabolic dysfunction-associated fatty liver disease using obese mouse models. Zool Res. 2020;41:539–51.
Sellmann C, Jin CJ, Degen C, De Bandt J-P, Bergheim I. Oral glutamine supplementation protects female mice from nonalcoholic steatohepatitis. J Nutr. 2015;145:2280–6.
Add Comment